Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer

摘要: Introduction Currently, the inhibitor of epidermal growth factor receptor tyrosine kinase erlotinib is widely used for treatment non-small cell lung cancer. Patients with a mutation or deletion in gene will benefit most and are likely to receive drug long periods willing accept side effects if responding. Methods Twenty-two cases prolonged administration (at least 6 months) reported. Three specific described detail. Results In addition well-known such as folliculitis diarrhea, patients reported paronychia, fatigue, hair changes. Discussion After patients, initial persist while other inconvenient ones may develop. This lead dose reductions even cessation treatment.